Seattle’s Aurion Biotech announced Wednesday that it received special designations from the U.S. Food and Drug Administration that should speed up the development of its treatment for a common disease that damages the cornea and can result in vision loss.
The FDA granted Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Aurion’s cell therapy treatment.
The designations accelerate the FDA’s review process, and are given to efforts that target serious diseases and offer significant improvements over currently available options.